Last reviewed · How we verify
Golimumab (GLM)
Golimumab (GLM) is a TNF-α inhibitor (monoclonal antibody) Small molecule drug developed by University College Dublin. It is currently FDA-approved for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
Golimumab is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine driving immune-mediated diseases.
Golimumab is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine driving immune-mediated diseases. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
At a glance
| Generic name | Golimumab (GLM) |
|---|---|
| Sponsor | University College Dublin |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Golimumab binds to and neutralizes TNF-α, preventing its interaction with TNF receptors on immune cells and reducing the inflammatory cascade. This suppresses the pathogenic immune response in autoimmune and inflammatory conditions. By inhibiting TNF-α signaling, it reduces joint inflammation, systemic inflammation, and disease progression in conditions like rheumatoid arthritis and inflammatory bowel disease.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Ulcerative colitis
- Crohn's disease
Common side effects
- Infections (including serious infections)
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
- Malignancy risk
Key clinical trials
- Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038) (PHASE4)
- The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) (PHASE4)
- Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis (PHASE4)
- Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) (PHASE3)
- An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Golimumab (GLM) CI brief — competitive landscape report
- Golimumab (GLM) updates RSS · CI watch RSS
- University College Dublin portfolio CI
Frequently asked questions about Golimumab (GLM)
What is Golimumab (GLM)?
How does Golimumab (GLM) work?
What is Golimumab (GLM) used for?
Who makes Golimumab (GLM)?
What drug class is Golimumab (GLM) in?
What development phase is Golimumab (GLM) in?
What are the side effects of Golimumab (GLM)?
What does Golimumab (GLM) target?
Related
- Drug class: All TNF-α inhibitor (monoclonal antibody) drugs
- Target: All drugs targeting TNF-α (Tumor Necrosis Factor-alpha)
- Manufacturer: University College Dublin — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Ankylosing spondylitis
- Indication: Drugs for Psoriatic arthritis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing